The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Targeting the transferrin receptor to transport antisense oligonucleotides across the mammalian blood-brain barrier
Abstract
Antisense oligonucleotides (ASOs) are promising therapeutics for treating various neurological disorders. However, ASOs are unable to readily cross the mammalian blood-brain barrier (BBB) and therefore need to be delivered intrathecally to the central nervous system (CNS). Here, we engineered a human transferrin receptor 1 (TfR1) binding molecule, the oligonucleotide transport vehicle (OTV), to transport a tool ASO across the BBB in human TfR knockin (TfR mu/hu KI) mice and nonhuman primates. Intravenous injection and systemic delivery of OTV to TfR mu/hu KI mice resulted in sustained knockdown of the ASO target RNA, Malat1 , across multiple mouse CNS regions and cell types, including endothelial cells, neurons, astrocytes, microglia, and oligodendrocytes. In addition, systemic delivery of OTV enabled Malat1 RNA knockdown in mouse quadriceps and cardiac muscles, which are difficult to target with oligonucleotides alone. Systemically delivered OTV enabled a more uniform ASO biodistribution profile in the CNS of TfR mu/hu KI mice and greater knockdown of Malat1 RNA compared with a bivalent, high-affinity TfR antibody. In cynomolgus macaques, an OTV directed against MALAT1 displayed robust ASO delivery to the primate CNS and enabled more uniform biodistribution and RNA target knockdown compared with intrathecal dosing of the same unconjugated ASO. Our data support systemically delivered OTV as a potential platform for delivering therapeutic ASOs across the BBB.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, intrathecally administered compounds must travel further along the spinal cord before reaching rostral brain regions [47].”
From Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid (2025) · cites this paper as [47]
In the citing paper
“numerous studies suggest that ASOs are not well suited for deep brain structure targets [16,47,52].”
From Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid–siRNA conjugate administered into cerebrospinal fluid (2025) · cites this paper as [47]
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The single-cell transcriptional landscape of mammalian organogenesis
Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D. M., Hill, A. J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F. J., et al. (2019) · Nature · doi:10.1038/s41586-019-0969-x · Cited by 4,490
Molecular Architecture of the Mouse Nervous System
Zeisel, A., Hochgerner, H., Lönnerberg, P., Johnsson, A., Memic, F., van der Zwan, J., Häring, M., Braun, E., Borm, L. E., La Manno, G., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.021 · Cited by 2,552
Advances in oligonucleotide drug delivery
Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,121
Diffusion in Brain Extracellular Space
Syková, E., & Nicholson, C. (2008) · Physiological Reviews · doi:10.1152/physrev.00027.2007 · Cited by 1,481
Bennett, C. F., & Swayze, E. E. (2010) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,431
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Geary, R. S., Norris, D. A., Yu, R. Z., & Bennett, C. F. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.008 · Cited by 870
Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622
Miller, T. M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S. H., Andres, P. L., Mahoney, K., Allred, P., Alexander, K., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70061-9 · Cited by 617
Nieto, M., Monuki, E. S., Tang, H., Imitola, J., Haubst, N., Khoury, S. J., Cunningham, J., Götz, M., & Walsh, C. A. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.20322 · Cited by 569
Research works printed but not linked: 1
- BioMarin Pharmaceutical (Canada) Inc. Pharmacoeconomic Review Report: Cerliponase Alfa (Brineura): Indication: For the Treatment of Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease Also Known as Tripeptidyl Peptidase 1 (TPP1) Deficiency (Canadian Agency for Drugs and Technologies in Health 2019).
Cited by
Sorted by citations
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 109
Lipid nanoparticles for mRNA delivery in brain via systemic administration
Cao, D., Hou, X., Wang, C., Wang, S., Liu, Z., Tian, M., Guo, K., Li, H., Kang, D. D., Zhong, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw0730 · Cited by 79
Khoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 78
Self-citationJiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63
Ding, L., Kshirsagar, P., Agrawal, P., & Murry, D. J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17060706 · Cited by 62
Metadata
- Authors
- Barker, S. J., Thayer, M. B., Kim, C., Tatarakis, D., Simon, M. J., Dial, R., Nilewski, L., Wells, R. C., Zhou, Y., Afetian, M., Akkapeddi, P., Chappell, A., Chew, K. S., Chow, J., Clemens, A., Discenza, C. B., Dugas, J. C., Dwyer, C., Earr, T., Ha, C., Ho, Y. S., Huynh, D., Lozano, E. I., Jayaraman, S., Kwan, W., Mahon, C., Pizzo, M., Robles-Colmenares, Y., Roche, E., Sanders, L., Stergioulis, A., Tong, R., Tran, H., Zuchero, Y., Estrada, A. A., Gadkar, K., Koth, C. M. M., Sanchez, P. E., Thorne, R. G., Watts, R. J., Sandmann, T., Kane, L. A., Rigo, F., Dennis, M. S., Lewcock, J. W., & DeVos, S. L.
- Affiliations
- Denali Therapeutics (United States) (US)
- Ionis Pharmaceuticals (United States) (US)
- Denali Therapeutics Inc., South San Francisco, CA, USA.
- Corresponding author
- Barker, Scarlett J.
- Thayer, Mai B.
- Kim, Chaeyoung
- Tatarakis, David
- ORCID
- Barker, Scarlett J.
- Thayer, Mai B.
- Kim, Chaeyoung
- Tatarakis, David
- Simon, Matthew J.
- Dial, Rebekah
- Nilewski, Lizanne
- Wells, Robert C.
- Afetian, Megan
- Akkapeddi, Padma
- Chappell, Alfred
- Chew, Kylie S.
- Chow, Johann
- Discenza, Claire B.
- Dugas, Jason C.
- Dwyer, Chrissa
- Earr, Timothy
- Ha, Connie
- Jayaraman, Srini
- Mahon, Cathal
- Pizzo, Michelle
- Robles-Colmenares, Yaneth
- Sanders, Laura
- Stergioulis, Alexander
- Tong, Raymond
- Tran, Hai
- Zuchero, Y.
- Estrada, Anthony A.
- Gadkar, Kapil
- Koth, Christopher M. M.
- Sanchez, Pascal E.
- Thorne, Robert G.
- Watts, Ryan J.
- Sandmann, Thomas
- Kane, Lesley A.
- Rigo, Frank
- Dennis, Mark S.
- Lewcock, Joseph W.
- DeVos, Sarah L.
- Venue
- Science Translational Medicine
- Published
- 2024-08-14
- Volume
- 16
- Issue
- 760
- Pages
- eadi2245-eadi2245
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W4401596729
- Cited by
- 142
- References
- 70
- Citations by year
- 2026: 65 · 2025: 68 · 2024: 8
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- antisense oligonucleotides, blood-brain barrier, transferrin receptor 1, MALAT1, brain drug delivery, systemic drug delivery, cynomolgus macaques, RNA knockdown, intrathecal drug delivery, tissue distribution
- MeSH terms
- Animals, Biological Transport, Blood-Brain Barrier, Humans, Macaca fascicularis, Receptors, Transferrin, Tissue Distribution, Oligonucleotides, Antisense, Mice, Gene Knockdown Techniques, RNA, Long Noncoding
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
